Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era

Allogeneic hematopoietic stem cell transplantation (HCT) remains a potentially curative option for CML patients who have failed multiple tyrosine kinase inhibitors (TKI ’s) or progressed to advanced disease. In patients with TKI failure, the majority (89%) responded to HCT with 68% achieving at least a major molecular response (MMR) [1]. Disease phase, found to be a major prognostic factor affecting transplant outcomes in the pre-TKI era, remains significant in t he TKI era. The 3-year survival rate has been reported as 91% in chronic phase (CP) vs 59% in advanced disease phase patients transplanted in the TKI-era [2].

Source: Leukemia Research - September 5, 2018 Category: Hematology Authors: Mary Lynn Savoie, Isabelle Bence-Bruckler, Lothar B. Huebsch, Marc Lalancette, Chris Hillis, Irwin Walker, Jeffrey H. Lipton, Donna L. Forrest, Dennis (Dong Hwan) Kim Tags: Research paper Source Type: research